Severe bronchiectasis
- PMID: 14716069
- DOI: 10.1385/CRIAI:25:3:233
Severe bronchiectasis
Abstract
Bronchiectasis is primarily the result of airway injury and remodeling attributable to recurrent or chronic inflammation and infection. The underlying etiologies include autoimmune diseases, severe infections, genetic abnormalities, and acquired disorders. Recurrent airway inflammation and infection may also be the result of allergic or immunodeficiency states such as allergic bronchopulmonary mycoses or HIV/AIDS. Bronchiectasis should be included in the differentiation diagnosis of any patient with chronic respiratory complaints such as cough and sputum production. Early clinical manifestations may be subtle. Hallmarks of severe bronchiectasis include fetid breath, chronic cough, and sputum production. The associated chronic respiratory infections and airway sepsis are punctuated by episodes of acute exacerbation. Prompt recognition and treatment of bronchiectasis may allow for prevention of disease progression and irreversible loss of lung function. This review of severe non-cystic fibrosis bronchiectasis describes the current pathophysiology, clinical presentations, and management of bronchiectasis. We review how impaired airway clearance and the inability to resolve infection and inflammation creates a vicious cycle of recurrent injury. The common clinical features of bronchiectasis and findings are presented and illustrated by radiographic images. The common species and significance of various organisms often recovered from the distal airways including: tuberculous and environmental mycobacteria, aspergillus, and bacteria such as Pseudomonas aeruginosa will be covered. Management strategies including sputum surveillance, sputum clearance, antimicrobial therapy including antifungal and antimyobacterial agents as well as the evidence for the use of inhalational and anti-inflammatory therapies such as corticosteroids are also discussed. Recommendations for the work-up and therapy of complications including hemoptysis and respiratory failure are presented.
Similar articles
-
Non-cystic fibrosis bronchiectasis.J R Coll Physicians Edinb. 2011 Jun;41(2):132-9; quiz 139. doi: 10.4997/JRCPE.2011.217. J R Coll Physicians Edinb. 2011. PMID: 21677919 Review.
-
Non-cystic fibrosis bronchiectasis.Am J Respir Crit Care Med. 2013 Sep 15;188(6):647-56. doi: 10.1164/rccm.201303-0411CI. Am J Respir Crit Care Med. 2013. PMID: 23898922 Review.
-
Infection prevention and chronic disease management in cystic fibrosis and noncystic fibrosis bronchiectasis.Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620905272. doi: 10.1177/1753466620905272. Ther Adv Respir Dis. 2020. PMID: 32160809 Free PMC article. Review.
-
Non-cystic fibrosis bronchiectasis: clinical presentation, diagnosis and treatment, illustrated by data from a Dutch Teaching Hospital.Neth J Med. 2015 May;73(4):147-54. Neth J Med. 2015. PMID: 25968285 Review.
-
Bronchiectasis.Presse Med. 2023 Sep;52(3):104174. doi: 10.1016/j.lpm.2023.104174. Epub 2023 Sep 30. Presse Med. 2023. PMID: 37778637 Review.
Cited by
-
Diagnostic yield of bronchial washing fluid analysis for hemoptysis in patients with bronchiectasis.Yonsei Med J. 2014 May;55(3):739-45. doi: 10.3349/ymj.2014.55.3.739. Epub 2014 Apr 1. Yonsei Med J. 2014. PMID: 24719142 Free PMC article.
-
Medicinal Plants in the Treatment of Respiratory Diseases and their Future Aspects.Recent Pat Biotechnol. 2025;19(1):2-18. doi: 10.2174/0118722083278561231212072408. Recent Pat Biotechnol. 2025. PMID: 38275072 Review.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
